DDInter1042 DDInter1432
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Perphenazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Perphenazine {u} (Compound) resembles {v} (Compound) Propericiazine
Perphenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Perphenazine {u} (Compound) binds {v} (Gene) CYP2C18
Perphenazine {u} (Compound) upregulates {v} (Gene) ST3GAL5
Perphenazine {u} (Compound) palliates {v} (Disease) Gilles de la Tourette syndrome
Perphenazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Perphenazine {u} (Compound) downregulates {v} (Gene) TXNDC9
Perphenazine {u} (Compound) causes {v} (Side Effect) Nocturnal confusion
Perphenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Perphenazine (Compound) resembles Triflupromazine (Compound)
Perphenazine (Compound) resembles Propericiazine (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Perphenazine (Compound) binds CYP2C18 (Gene)
Perphenazine (Compound) upregulates ST3GAL5 (Gene)
Perphenazine (Compound) palliates Gilles de la Tourette syndrome (Disease)
Perphenazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Perphenazine (Compound) downregulates TXNDC9 (Gene)
Perphenazine (Compound) causes Nocturnal confusion (Side Effect)
Perphenazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate